Cargando…
Histopathologic and Flow-Cytometric Analysis of Neoplastic and Benign “background” Tissue in Breast Carcinoma Resections
Two-color, multiparametric synthesis phase fraction (SPF) analysis of cytokeratin-labeled epithelial cells was flow cytometrically performed on both benign (SPFb) and malignant tissue samples (if available, SPFt) from 132 mastectomy/lumpectomy specimens. These data were then correlated with clinicop...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615298/ https://www.ncbi.nlm.nih.gov/pubmed/10221331 http://dx.doi.org/10.1155/1998/294903 |
_version_ | 1782396480271679488 |
---|---|
author | Visscher, Daniel W. Gingrich, Debra S. Leon-Armin, Carmen Tabaczka, Pamela Crissman, John D. |
author_facet | Visscher, Daniel W. Gingrich, Debra S. Leon-Armin, Carmen Tabaczka, Pamela Crissman, John D. |
author_sort | Visscher, Daniel W. |
collection | PubMed |
description | Two-color, multiparametric synthesis phase fraction (SPF) analysis of cytokeratin-labeled epithelial cells was flow cytometrically performed on both benign (SPFb) and malignant tissue samples (if available, SPFt) from 132 mastectomy/lumpectomy specimens. These data were then correlated with clinicopathologic features, including (1) tumor differentiation, (2) the proportion of tumor comprised of duct carcinoma-in situ (DCIS), and (3) the histology of accompanying benign breast tissue, classified by predominant microscopic pattern as intact, normal terminal duct lobular units (NTDLU, 34% of cases), atrophic (AT, 33% of cases), proliferative fibrocystic (PFC, 26% of cases), and non-proliferative fibrocystic (NPFC, 7% of cases). SPFt was inversely correlated with extent of DCIS (DCIS =0 – 20% tumor volume – 12.7% mean SPFt, vs. DCIS >20% tumor volume – 6.4% mean SPFt, p = 0.001). SPFt also correlated with the histology of background benign breast tissue (NTDLU – 14.8% mean SPFt vs. AT – 6.9% mean SPFt vs. PFC – 12.7% mean SPFt, p = 0.05) but it did not correlate with patient age or SPFb (overall mean =0.73%). SPFb was correlated with patient age (>56 yr – 0.59% mean SPFb vs. < yr – 0.84% mean SPFb, p = 0.02), with background histology (NTDLU – 1.1% mean SPFb vs. AT – 0.43% mean SPFb vs. PFC – 0.70% mean SPFb, p < 0.02) and with the grade of the neoplasm (well/moderate – 0.58% mean vs. poorly differentiated – 0.85% mean, p = 0.04). Patients having a background of PFC were significantly older than patients with a background of NTDLU (45.2 yr vs. 60.2 yr, p = 0.01). We conclude: (1) breast carcinomas arising from a background of more actively cycling pre-involutional or proliferative fibrocystic epithelium have a greater proliferative fraction than tumors arising from atrophic epithelium, implying that the differentiation status of target cells may impact the effect(s) of tumorigenic events; (2) PFC may represent delayed, abnormal or interrupted involution rather than a hyperproliferative state relative to NTDLU, suggesting that it facilitates neoplasia by extending the period of exposure to promoter agents such as endogenous hormones, and (3) lower SPFt in breast neoplasia with more abundant “residual” DCIS may reflect a lengthier pre-invasive disease interval due to intrinsically less aggressive phenotype. |
format | Online Article Text |
id | pubmed-4615298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1998 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46152982016-01-12 Histopathologic and Flow-Cytometric Analysis of Neoplastic and Benign “background” Tissue in Breast Carcinoma Resections Visscher, Daniel W. Gingrich, Debra S. Leon-Armin, Carmen Tabaczka, Pamela Crissman, John D. Anal Cell Pathol Other Two-color, multiparametric synthesis phase fraction (SPF) analysis of cytokeratin-labeled epithelial cells was flow cytometrically performed on both benign (SPFb) and malignant tissue samples (if available, SPFt) from 132 mastectomy/lumpectomy specimens. These data were then correlated with clinicopathologic features, including (1) tumor differentiation, (2) the proportion of tumor comprised of duct carcinoma-in situ (DCIS), and (3) the histology of accompanying benign breast tissue, classified by predominant microscopic pattern as intact, normal terminal duct lobular units (NTDLU, 34% of cases), atrophic (AT, 33% of cases), proliferative fibrocystic (PFC, 26% of cases), and non-proliferative fibrocystic (NPFC, 7% of cases). SPFt was inversely correlated with extent of DCIS (DCIS =0 – 20% tumor volume – 12.7% mean SPFt, vs. DCIS >20% tumor volume – 6.4% mean SPFt, p = 0.001). SPFt also correlated with the histology of background benign breast tissue (NTDLU – 14.8% mean SPFt vs. AT – 6.9% mean SPFt vs. PFC – 12.7% mean SPFt, p = 0.05) but it did not correlate with patient age or SPFb (overall mean =0.73%). SPFb was correlated with patient age (>56 yr – 0.59% mean SPFb vs. < yr – 0.84% mean SPFb, p = 0.02), with background histology (NTDLU – 1.1% mean SPFb vs. AT – 0.43% mean SPFb vs. PFC – 0.70% mean SPFb, p < 0.02) and with the grade of the neoplasm (well/moderate – 0.58% mean vs. poorly differentiated – 0.85% mean, p = 0.04). Patients having a background of PFC were significantly older than patients with a background of NTDLU (45.2 yr vs. 60.2 yr, p = 0.01). We conclude: (1) breast carcinomas arising from a background of more actively cycling pre-involutional or proliferative fibrocystic epithelium have a greater proliferative fraction than tumors arising from atrophic epithelium, implying that the differentiation status of target cells may impact the effect(s) of tumorigenic events; (2) PFC may represent delayed, abnormal or interrupted involution rather than a hyperproliferative state relative to NTDLU, suggesting that it facilitates neoplasia by extending the period of exposure to promoter agents such as endogenous hormones, and (3) lower SPFt in breast neoplasia with more abundant “residual” DCIS may reflect a lengthier pre-invasive disease interval due to intrinsically less aggressive phenotype. IOS Press 1998 1998-01-01 /pmc/articles/PMC4615298/ /pubmed/10221331 http://dx.doi.org/10.1155/1998/294903 Text en Copyright © 1998 Hindawi Publishing Corporation. |
spellingShingle | Other Visscher, Daniel W. Gingrich, Debra S. Leon-Armin, Carmen Tabaczka, Pamela Crissman, John D. Histopathologic and Flow-Cytometric Analysis of Neoplastic and Benign “background” Tissue in Breast Carcinoma Resections |
title | Histopathologic and Flow-Cytometric Analysis of Neoplastic and Benign “background” Tissue in Breast Carcinoma Resections |
title_full | Histopathologic and Flow-Cytometric Analysis of Neoplastic and Benign “background” Tissue in Breast Carcinoma Resections |
title_fullStr | Histopathologic and Flow-Cytometric Analysis of Neoplastic and Benign “background” Tissue in Breast Carcinoma Resections |
title_full_unstemmed | Histopathologic and Flow-Cytometric Analysis of Neoplastic and Benign “background” Tissue in Breast Carcinoma Resections |
title_short | Histopathologic and Flow-Cytometric Analysis of Neoplastic and Benign “background” Tissue in Breast Carcinoma Resections |
title_sort | histopathologic and flow-cytometric analysis of neoplastic and benign “background” tissue in breast carcinoma resections |
topic | Other |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615298/ https://www.ncbi.nlm.nih.gov/pubmed/10221331 http://dx.doi.org/10.1155/1998/294903 |
work_keys_str_mv | AT visscherdanielw histopathologicandflowcytometricanalysisofneoplasticandbenignbackgroundtissueinbreastcarcinomaresections AT gingrichdebras histopathologicandflowcytometricanalysisofneoplasticandbenignbackgroundtissueinbreastcarcinomaresections AT leonarmincarmen histopathologicandflowcytometricanalysisofneoplasticandbenignbackgroundtissueinbreastcarcinomaresections AT tabaczkapamela histopathologicandflowcytometricanalysisofneoplasticandbenignbackgroundtissueinbreastcarcinomaresections AT crissmanjohnd histopathologicandflowcytometricanalysisofneoplasticandbenignbackgroundtissueinbreastcarcinomaresections |